GRAM POSITIVE BACTERIAL INFECTIONS MARKET ANALYSIS
Gram Positive Bacterial Infections Market, by Drug Class (Antibiotic (B Lactam, Quinolones, Macrolides, Tetracyclines, Aminoglycosides, Sulphonamides, Phenicols, and Others), Antifungal, and Others), by Indication (MRSA Infections, MSSA Infections, Sinusitis, Cellulitis, Pneumonia, Otitis, Pharyngitis, and Others), by Route of Administration (Enteral, Parenteral, and Others), by Distribution Channels (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2019 – 2026
Source
Bacteria are classified into two main types: gram positive bacteria and gram negative bacteria. After staining, gram positive bacteria shows violet purple color under microscope. Gram positive bacteria cause various infections such as Methicillin- resistant Staphylococcus aureus (MRSA) infections, Methicillin-Susceptible Staphylococcus aureus (MSSA) infections, sinusitis, cellulitis, and pneumonia.
Gram Positive Bacterial Infections Market Drivers
Increasing drug approvals are expected to propel growth of the gram positive bacterial infections market. For instance, in October 2018, Paratek Pharmaceuticals, Inc. received approval from the U.S. Food and Drug Administration for NUZYRA (for injection), which contains an Omadacycline. This drug is used for treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).
Increasing drug launches are expected to drive the gram positive bacterial infections market growth. For instance, in March 2017, Pfizer launched its new drug, Zavicefta, which contains combination of Avibactam and Ceftazidime. This drug is used for the treatment of intra- abdominal infections.
Gram Positive Bacterial Infections Market Restraints
Antibiotic resistance is the major problem in the treatment of gram positive bacterial infections, which is expected to hamper the market growth. For instance, in October 2018, according to the Centers for Disease Control (CDC) and Prevention, overdose of antibiotics can lead to resistance and around 2 million people are affected with antibiotic resistance in the U.S annually.
Gram Positive Bacterial Infections Market Regional Analysis
On the basis of region, the global gram positive bacterial infections market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is expected to hold dominant position in the gram positive bacterial infections market, owing to increasing launch of antibacterial drugs acting against gram positive bacteria. For instance, in January 2018, Melinta Therapeutics, Inc. launched its new drug, Baxdela antibiotic containing Delafloxacin, for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
Request Sample
https://www.coherentmarketinsights.com/insight/request-sample/2654
Download PDF
https://www.coherentmarketinsights.com/insight/request-pdf/2654
Europe is also expected to witness significant growth in the gram positive bacterial infections market, owing to increasing collaboration and acquisition activities adopted by market players. For instance, in March 2019, Evotec AG (headquartered in Germany) collaborated with the Global Antibiotic Research and Development Partnership (GARDP). This collaboration focuses on accelerating the development of novel antibiotic treatments.
Key players operating in the global gram positive bacterial infections market include, Merck & Co., Inc., AstraZeneca, Theravance Biopharma, Bristol-Myers Squibb Company, Novartis AG, Bayer AG, Pfizer, Inc., Sanofi, GlaxoSmithKline plc. (GSK),and Allergan plc.
Gram Positive Bacterial Infections Market Taxonomy
By Drug Class
- Antibiotic
- Quinolones
- Macrolides
- Tetracyclines
- Aminoglycosides
- Sulphonamides
- Phenicols
- Others
- Antifungal
- Others
By Indication
- MRSA Infections
- MSSA Infections
- Sinusitis
- Cellulitis
- Cellulitis
- Otitis
- Pharyngitis
- Others
By Route of Administration:
- Enteral
- Parenteral
- Others
By Distribution Channels
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.
What we provide:
- Customized Market Research Services
- Industry Analysis Services
- Business Consulting Services
- Market Intelligence Services
- Long term Engagement Model
- Country Specific Analysis
Mr. Shah
Coherent Market Insights Pvt. Ltd.
Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.
Phone: +1-206-701-6702
Email:Â [email protected]